Natera IPO
Natera is a genetic testing and diagnostics company that provides testing services across women's health, oncology, and organ transplantation. The company is known for its non-invasive prenatal testing (NIPT) and liquid biopsy technologies that analyze cell-free DNA in blood samples. Natera's tests help healthcare providers make informed decisions about pregnancy management, cancer treatment, and transplant monitoring.
Key Facts
| Industry | Genetic Testing & Diagnostics |
| Founded | 2004 |
| Headquarters | Austin, TX |
| Employees | ~2,000 |
| Website | natera.com |
| Funding | Public company (NASDAQ: NTRA) |
About Natera
Natera is a leading genetic testing company that specializes in cell-free DNA testing and genetic analysis across multiple medical applications. The company is best known for its non-invasive prenatal testing (NIPT) through products like Panorama, which screens for chromosomal abnormalities in developing fetuses using a simple blood draw from the mother. Beyond prenatal testing, Natera has expanded into oncology with liquid biopsy tests that detect circulating tumor DNA to monitor cancer treatment response and recurrence.
The company's proprietary SNP-based technology platform enables highly accurate genetic analysis from minimal DNA samples. Natera has built a comprehensive portfolio spanning reproductive health, oncology, and organ transplant monitoring, positioning itself as a key player in the precision medicine revolution. Their tests are used by healthcare providers worldwide to make critical medical decisions, from pregnancy management to cancer treatment optimization.
IPO Status
Natera went public in July 2015, trading on NASDAQ under the ticker symbol NTRA. The company's IPO raised approximately $52 million at $18 per share. Since going public, Natera has expanded its testing portfolio beyond women's health into oncology and transplant medicine, growing through both organic development and strategic acquisitions. As a public company, Natera has focused on advancing its liquid biopsy technology and expanding market adoption of its tests. The company has invested heavily in clinical studies to support the clinical utility of its tests and has worked to secure reimbursement coverage from payers. Natera has also expanded internationally and formed partnerships with healthcare systems and other companies.
Competitors
Frequently Asked Questions
Does Natera have a stock?
Yes, Natera has been a public company since July 2015. The company went public on NASDAQ under the ticker symbol NTRA.
When is the Natera IPO date?
Natera completed its IPO in July 2015, raising approximately $52 million at $18 per share. The company has been publicly traded for nearly a decade.
How can I buy Natera stock?
You can buy Natera stock through any brokerage account as it trades publicly on NASDAQ under the ticker symbol NTRA. The stock is available through standard online and traditional brokerage services.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts